These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 33248445)

  • 1. Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis.
    Piccoli GF; Mesquita LA; Stein C; Aziz M; Zoldan M; Degobi NAH; Spiazzi BF; Lopes Junior GL; Colpani V; Gerchman F
    J Clin Endocrinol Metab; 2021 Mar; 106(3):912-921. PubMed ID: 33248445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
    Guo X; Yang Q; Dong J; Liao L; Zhang W; Liu F
    Clin Drug Investig; 2016 Jun; 36(6):433-41. PubMed ID: 26979594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.
    Siskind D; Hahn M; Correll CU; Fink-Jensen A; Russell AW; Bak N; Broberg BV; Larsen J; Ishøy PL; Vilsbøll T; Knop FK; Kisely S; Ebdrup BH
    Diabetes Obes Metab; 2019 Feb; 21(2):293-302. PubMed ID: 30187620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.
    Storgaard H; Cold F; Gluud LL; Vilsbøll T; Knop FK
    Diabetes Obes Metab; 2017 Jun; 19(6):906-908. PubMed ID: 28105738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Banerjee M; Pal R; Mukhopadhyay S; Nair K
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1806-1812. PubMed ID: 36800286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.
    Guo X; Zhou Z; Lyu X; Xu H; Zhu H; Pan H; Wang L; Yang H; Gong F
    Horm Metab Res; 2022 Jul; 54(7):458-471. PubMed ID: 35512849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials.
    Cao C; Yang S; Zhou Z
    Endocrine; 2019 Nov; 66(2):157-165. PubMed ID: 31420784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.
    Li L; Li S; Liu J; Deng K; Busse JW; Vandvik PO; Wong E; Sohani ZN; Bala MM; Rios LP; Malaga G; Ebrahim S; Shen J; Zhang L; Zhao P; Chen Q; Wang Y; Guyatt GH; Sun X
    BMC Cardiovasc Disord; 2016 May; 16():91. PubMed ID: 27169565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
    He L; Wang J; Ping F; Yang N; Huang J; Li Y; Xu L; Li W; Zhang H
    JAMA Intern Med; 2022 May; 182(5):513-519. PubMed ID: 35344001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): A systematic review and meta-analysis of observational cohort studies.
    Herrera Comoglio R; Vidal Guitart X
    Int J Clin Pract; 2020 Sep; 74(9):e13553. PubMed ID: 32452094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
    Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?
    Bai S; Lin C; Jiao R; Cai X; Hu S; Lv F; Yang W; Zhu X; Ji L
    Eur J Intern Med; 2023 Mar; 109():79-88. PubMed ID: 36628824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
    Wong SY; Lee ARYB; Sia AHJ; Wo YJ; Teo YH; Teo YN; Syn NL; Ong CC; Teo LL; Yeo TC; Poh KK; Kong WK; Wong RC; Sia CH
    Cardiovasc Drugs Ther; 2024 Apr; 38(2):371-389. PubMed ID: 35819544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Association between GLP-1 Receptor-Based Agonists and the Incidence of Asthma in Patients with Type 2 Diabetes and/or Obesity: A Meta-Analysis.
    Zhang MQ; Lin C; Cai XL; Jiao RY; Bai SZ; Li ZL; Hu SY; Lyu F; Yang WJ; Ji LN
    Biomed Environ Sci; 2024 Jun; 37(6):607-616. PubMed ID: 38988111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.
    Alkhezi OS; Alahmed AA; Alfayez OM; Alzuman OA; Almutairi AR; Almohammed OA
    Obes Rev; 2023 Mar; 24(3):e13543. PubMed ID: 36579723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes.
    Wang L; Xu R; Kaelber DC; Berger NA
    JAMA Netw Open; 2024 Jul; 7(7):e2421305. PubMed ID: 38967919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.
    Liu Y; Ruan B; Jiang H; Le S; Liu Y; Ao X; Huang Y; Shi X; Xue R; Fu X; Wang S
    Am J Clin Nutr; 2023 Sep; 118(3):614-626. PubMed ID: 37661106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis.
    Liu Y; Zhang X; Chai S; Zhao X; Ji L
    J Diabetes Res; 2019; 2019():1534365. PubMed ID: 31396537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.